Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bauer

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
The Lancet. Neurology|September 15, 2009
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Annals of the Rheumatic Diseases|January 19, 2018
Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trialDésirée van der Heijde, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
The New England Journal of Medicine|January 26, 2007
Lack of association between antimyelin antibodies and progression to multiple sclerosisJens Kuhle, Christoph Pohl, Matthias Mehling, et al.
Neurology|May 11, 2016
Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCTAxel Bauer, Werner Cassel, Heike Benes, et al.
Rheumatology (Oxford, England)|May 13, 2017
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpADésirée van der Heijde, Maxime Dougados, Robert Landewé, et al.
Radiology|November 28, 2008
Subtraction MR images in a multiple sclerosis multicenter clinical trial settingBastiaan Moraal, Dominik S Meier, Peter A Poppe, et al.
Archives of Neurology|September 12, 2007
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year resultsFrederik Barkhof, Chris H Polman, Ernst-Wilhelm Radue, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
The Lancet. Neurology|September 15, 2009
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Annals of the Rheumatic Diseases|January 19, 2018
Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trialDésirée van der Heijde, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
The New England Journal of Medicine|January 26, 2007
Lack of association between antimyelin antibodies and progression to multiple sclerosisJens Kuhle, Christoph Pohl, Matthias Mehling, et al.
Neurology|May 11, 2016
Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCTAxel Bauer, Werner Cassel, Heike Benes, et al.
Rheumatology (Oxford, England)|May 13, 2017
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpADésirée van der Heijde, Maxime Dougados, Robert Landewé, et al.
Radiology|November 28, 2008
Subtraction MR images in a multiple sclerosis multicenter clinical trial settingBastiaan Moraal, Dominik S Meier, Peter A Poppe, et al.
Archives of Neurology|September 12, 2007
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year resultsFrederik Barkhof, Chris H Polman, Ernst-Wilhelm Radue, et al.
Pageof 5